← Back to Search

Patient Navigation for Timely Breast Cancer Diagnosis During COVID-19

N/A

Recruiting

Led By Eniola Oluyemi

Research Sponsored by Johns Hopkins University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients who have an abnormal screening mammogram (i.e. given a Breast Imaging-Reporting and Data System [BI-RADS] assessment category of 0) at the investigators' institution during the study period and have not yet undergone diagnostic evaluation

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 30 days after the screening mammogram

Awards & highlights

Study Summary

This trial will evaluate whether patient navigation can help reduce delays in breast cancer diagnosis caused by the COVID-19 pandemic.

Who is the study for?

This trial is for patients with abnormal breast screening results during the COVID-19 pandemic who haven't had further diagnostic evaluation. It's aimed at those most affected by delays in follow-up due to the pandemic. Participants must be able to give consent.Check my eligibility

What is being tested?

The study is testing if patient navigator support can help people get timely follow-up care after an abnormal mammogram, especially during the disruptions caused by COVID-19. The goal is to see if this support reduces delays in diagnosing breast cancer.See study design

What are the potential side effects?

Since this trial involves patient navigation rather than a medical treatment or drug, there are no direct side effects associated with it like you might expect from medication.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My recent mammogram was abnormal, and I haven't had further tests yet.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 30 days after the screening mammogram

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~30 days after the screening mammogram

This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 days after the screening mammogram for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Diagnostic follow-up rates

Secondary outcome measures

Anxiety level as assessed by the Spielberger State-Trait Anxiety Inventory

Breast cancer worry as assessed by the Lerman Breast Cancer Worry Scale

Trial Design

2Treatment groups

Active Control

Group I: Usual care groupActive Control1 Intervention

The study participants in this group will receive the usual care per the institutional protocol.

Group II: Intervention groupActive Control1 Intervention

The study participants in this group will receive support from the patient navigator as part of this study.

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Johns Hopkins UniversityLead Sponsor

2,262 Previous Clinical Trials

14,822,968 Total Patients Enrolled

27 Trials studying Breast Cancer

23,312 Patients Enrolled for Breast Cancer

Association of University Radiologists (AUR) - GERRAFUNKNOWN

Eniola OluyemiPrincipal InvestigatorJohns Hopkins University

Media Library

Intervention group Clinical Trial Eligibility Overview. Trial Name: NCT05181722 — N/A

Breast Cancer Research Study Groups: Usual care group, Intervention group

Breast Cancer Clinical Trial 2023: Intervention group Highlights & Side Effects. Trial Name: NCT05181722 — N/A

Intervention group 2023 Treatment Timeline for Medical Study. Trial Name: NCT05181722 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are involved in this clinical research project?

"Affirmative. Clinicaltrials.gov data confirms that this research endeavour, which was originally posted on July 18th 2022, is presently recruiting for 196 participants from a single site."

Answered by AI

Are there opportunities for individuals to participate in this experiment?

"According to clinicaltrials.gov, this trial is open for recruitment as of today. It was originally advertised on July 18th 2022 and the information concerning it has been recently refreshed on July 28th 2022."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Evaluating the Use of Patient Navigation to Promote Timely Diagnostic Evaluation During the COVID-19 Pandemic

2022. "Evaluating the Use of Patient Navigation to Promote Timely Diagnostic Evaluation During the COVID-19 Pandemic". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05181722.